Seattle Genetics, Inc. : Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting
05/16/2012| 06:10pm US/Eastern
Recommend:
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two
of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab
vedotin) and ASG-5ME, will be presented at the American Society of
Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012
in Chicago, IL. A summary of the company's poster presentations is below
and full abstracts can be accessed on the ASCO website at www.abstract.asco.org.
ADCETRIS
Retreatment with brentuximab vedotin in CD30-positive hematologic
malignancies: a phase II study
-
Saturday, June 2; 8:00 a.m. - 1:00 p.m. Central Time (CT), with
discussion from 12:00 p.m. - 1:00 p.m. CT
-
Abstract # 8027
-
Poster display in room E450b and discussion in room E354a
-
First author: Dr. Nancy L. Bartlett, Washington University, Siteman
Cancer Center, St. Louis, MO
CD30 expression in non-lymphomatous malignancies
-
Monday, June 4; 8:00 a.m. - 12:00 p.m. CT
-
Abstract #3069
-
Poster presentation in S Hall A2; poster board #16C
-
First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute
and Research Center, Eugene, OR
Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma:
preliminary results from a phase II study
-
Monday, June 4; 1:15 p.m. - 5:15 p.m. CT
-
Abstract #8070
-
Poster presentation in S Hall A2; poster board #35C
-
First author: Dr. Ranjana Advani, Stanford University Medical Center,
Stanford, CA
ASG-5ME
Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate
cancer (CRPC)
-
Monday, June 4; 8:00 a.m. - 12:00 p.m. CT, with discussion from 11:30
a.m. - 12:30 p.m. CT
-
Abstract #4568
-
Poster display in room E450a and discussion in room E Arie Crown
Theater
-
First author: Dr. Michael J. Morris, Memorial Sloan Kettering Cancer
Center, New York, NY
About ADCETRIS
ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30
monoclonal antibody attached by a protease-cleavable linker to a
microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing
Seattle Genetics' proprietary technology. The ADC employs a linker
system that is designed to be stable in the bloodstream but to release
MMAE upon internalization into CD30-expressing tumor cells.
Seattle Genetics and Millennium: The Takeda Oncology Company are jointly
developing ADCETRIS.
Under the terms of the collaboration agreement, Seattle Genetics has
U.S. and Canadian commercialization rights and the Takeda Group has
rights to commercialize ADCETRIS in the rest of the world. Seattle
Genetics and the Takeda Group are funding joint development costs for
ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group is
solely responsible for development costs.
About ASG-5ME
ASG-5ME is an ADC targeting the SLC44A4 antigen and is being
co-developed by Seattle Genetics and Agensys, Inc., an affiliate of
Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors.
ASG-5ME is an ADC composed of a fully human antibody directed to
SLC44A4, a solute carrier antigen family member identified by Agensys to
be overexpressed in epithelial cancers, including more than 80 percent
of samples derived from patients with prostate, pancreatic and gastric
cancers. The antibody is attached to MMAE via an enzyme-cleavable linker
using Seattle Genetics' proprietary technology. The ADC is designed to
be stable in the bloodstream, but to release MMAE upon internalization
into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The U.S. Food and Drug Administration granted
accelerated approval of ADCETRIS in August 2011 for two indications.
ADCETRIS is being developed in collaboration with Millennium: The Takeda
Oncology Company. In addition, Seattle Genetics has three other
clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle
Genetics has collaborations for its ADC technology with a number of
leading biotechnology and pharmaceutical companies, including Abbott,
Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline,
Millennium, Pfizer and Progenics, as well as ADC co-development
agreements with Agensys, an affiliate of Astellas, and Genmab. More
information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
© Business Wire 2012
Recommend :
